Singapur - inglise - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - inactivated poliomyelitis virus type 1 (mahoney); inactivated poliomyelitis virus type 2 (mef-1); inactivated poliomyelitis virus type 3 (saukett) - injection - 8 d.u. - inactivated poliomyelitis virus type 1 (mahoney) 40 d.u./0.5 ml; inactivated poliomyelitis virus type 2 (mef-1) 8 d.u./0.5 ml; inactivated poliomyelitis virus type 3 (saukett) 32 d.u./0.5 ml

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b );  ; influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275);  ; influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 );   - solution for injection - 0.5 ml - active: influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b )   influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275)   influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 )   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin potassium chloride sodium chloride water for injection - vaxigrip is indicated for the prevention of influenza caused by influenza virus types a and b in adults and children aged 6 months and over.

Singapur - inglise - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - haemophilus influenza type b polysaccharide conjugated to tetanus protein - injection, powder, for solution - 10 mcg expressd as amount of polysaccharide containing 8.4% of phosphorous

Saudi Araabia - inglise - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi pasteur, france - influenza a virus a/indonesia/5/2005 (h5n1) antigen (uv, formaldehyde inactivated) - suspension for injection in pre-filled syringe - 15 µg,

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -

Singapur - inglise - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose

Singapur - inglise - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - bacillus calmette-guerin - injection, powder, lyophilized, for solution - 81mg/vial

Singapur - inglise - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 48 microgram; meningococcal polysaccharide group y, quantity: 4 microgram; meningococcal polysaccharide group w135, quantity: 4 microgram; meningococcal polysaccharide group c, quantity: 4 microgram; meningococcal polysaccharide group a, quantity: 4 microgram - injection, solution - excipient ingredients: monobasic sodium phosphate; sodium chloride; dibasic sodium phosphate - menactra is indicated for active immunisation of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.,menactra is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b.,menactra is not indicated for treatment of meningococcal infections.,menactra is not indicated for immunisation against diphtheria.